...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Case Reports in Cardiology >“First in Man”: Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction
【24h】

“First in Man”: Case Report of Selective C-Reactive Protein Apheresis in a Patient with Acute ST Segment Elevation Myocardial Infarction

机译：“首例”：急性ST段抬高型心肌梗死患者选择性C反应蛋白置换的病例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

C-reactive protein (CRP) may be causative in cardiovascular disease. As yet, no specific CRP inhibitor for human application has been described. A 69-year-old male was referred with ST segment elevation myocardial infarction (STEMI). Typical symptoms of chest pain started at 10.00 p.m. The patient was admitted to the hospital at 1.30 a.m. the next day. As ECG showed anterior wall myocardial infarction, the patient was immediately transferred to successful emergency angioplasty/drug-eluting- (DE-) stenting of the subtotally occluded left anterior descending artery. Consecutively, the hemodynamically stable patient was monitored at the chest pain unit. C-reactive protein (CRP) apheresis using the CRP adsorber (PentraSorb® CRP) within CAMI-1 trial was performed 34 h and 58 h after the onset of symptoms. In each apheresis session, 6000 ml plasma was treated via peripheral venous access. Plasma CRP levels decreased from 28.77 mg/l to 12.58 mg/l during the first apheresis session and from 24.17 mg/l to 11.55 mg/l during the second session, respectively. No side effects were observed. This is the first report of selective CRP apheresis in a man. The technology offers multiple opportunities to clarify the immunological/pathogenic role of CRP in health and disease.
机译：C反应蛋白（CRP）可能是心血管疾病的病因。迄今为止，尚未描述用于人的特异性CRP抑制剂。一名69岁男性因ST段抬高型心肌梗塞（STEMI）转诊。胸痛的典型症状始于下午10:00。该患者第二天凌晨1.30被送入医院。由于心电图显示前壁心肌梗塞，患者立即被转移至完全阻塞的左前降支动脉成功进行了紧急血管成形术/药物洗脱-（DE-）支架。连续在胸痛病房监测血流动力学稳定的患者。 CAMI-1试验中使用CRP吸附剂（PentraSorb®CRP）进行C反应蛋白（CRP）血液分离在症状发作后34 h和58 h进行。在每次血液采血过程中，通过外周静脉通路治疗了6000μml血浆。在第一次单采过程中，血浆CRP水平分别从28.77μg/ l降至12.58μg/ l，在第二次血浆中从24.17μg/ l降至11.55μg/ l。没有观察到副作用。这是男性选择性CRP血液分离的首次报道。该技术提供了多种机会来阐明CRP在健康和疾病中的免疫学/致病作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号